This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioScrip's CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

BioScrip Inc. (BIOS)

Bank of America Merrill Lynch 2012 Health Care Conference Transcript

May 17, 2012 3:40 PM ET


Rick Smith – President and CEO



Unidentified Analyst

…this afternoon for, I guess, last but not least for our final presentation of the conference. But with the final presentation we have Rick Smith, the President and CEO of BioScrip. Thank you, Rick for joining us…

Rick Smith

Thank you.

Unidentified Analyst

…and let’s take it away.

Rick Smith

Okay. Good afternoon. Here is a Safe Harbor for your information. The BioScrip has been going under series of steps of transformation over the last 15 months. As of for 2011 our total revenue size is about a $1.8 billion in revenue and as part of our transformation we had made a decision to sell certain parts of our business that represent about a $1.2 billion revenue is more in the areas of our specialty pharmacy and legacy community, specialty pharmacy retail stores, and our traditional mail business.

What we have, last is essentially the focus area and that is Home Infusion, which based on our Q1 2012 revenue about $109 million, a Home Health segment that we acquired through the acquisition of CHS about $16.7 million represented for the quarter. And then one of the remaining segments of our Pharmacy Services is PBM and Cash Card legacy business that generate about $30 million in revenue for Q1 as well.

Our focus now and as we’ve talked about is, is really to becoming national platform in Home Infusion, a lot of the efforts that we’ve essentially put in place over the last couple of years is really to position ourselves from a contracting perspective and also to expand our infusion footprint.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs